share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  06/04 16:18
Moomoo AI 已提取核心信息
Heart Test Laboratories, Inc., also known as HeartSciences, has successfully regained compliance with the Nasdaq's minimum bid price requirement, as confirmed by a letter from The Nasdaq Stock Market LLC received on June 3, 2024. The company's common stock had previously failed to meet the $1.00 minimum closing bid price for 30 consecutive business days, leading to non-compliance notification from Nasdaq on August 2, 2023. To rectify this, HeartSciences was required to maintain a closing bid price of at least $1.00 for 10 consecutive trading days, a condition it fulfilled by May 31, 2024. As a result, the scheduled appeal hearing on June 27, 2024, has been canceled, and the company's common stock and warrants will continue to be listed on the Nasdaq. HeartSciences, a medical technology company leveraging AI to enhance ECGs for early heart disease detection, announced the compliance achievement in a press release on June 4, 2024. The company is developing AI-ECG solutions and is working towards FDA clearance for its MyoVista® wavECG™ device.
Heart Test Laboratories, Inc., also known as HeartSciences, has successfully regained compliance with the Nasdaq's minimum bid price requirement, as confirmed by a letter from The Nasdaq Stock Market LLC received on June 3, 2024. The company's common stock had previously failed to meet the $1.00 minimum closing bid price for 30 consecutive business days, leading to non-compliance notification from Nasdaq on August 2, 2023. To rectify this, HeartSciences was required to maintain a closing bid price of at least $1.00 for 10 consecutive trading days, a condition it fulfilled by May 31, 2024. As a result, the scheduled appeal hearing on June 27, 2024, has been canceled, and the company's common stock and warrants will continue to be listed on the Nasdaq. HeartSciences, a medical technology company leveraging AI to enhance ECGs for early heart disease detection, announced the compliance achievement in a press release on June 4, 2024. The company is developing AI-ECG solutions and is working towards FDA clearance for its MyoVista® wavECG™ device.
Heart Test Laboratories, Inc.，也称HeartSciences，已成功恢复纳斯达克最低买入价格要求的合规性，这得到了纳斯达克证券市场有限责任公司于2024年6月3日收到的一封信的确认。该公司的普通股此前未能连续30个营业日满足每日最低收盘竞价为1.00美元的要求，导致在2023年8月2日，纳斯达克发出了不符合要求的通知。为了纠正这一状况，HeartSciences需要连续10个交易日保持收盘竞价至少为1.00美元，该条件已在2024年5月31日之前满足。因此，原定于2024年6月27日的上诉听证会已被取消，该公司的普通股和认股权证将继续在纳斯达克上市。利用人工智能改善心电图以早期检测心脏疾病的医疗技术公司HeartSciences于2024年6月4日发布新闻公告宣布了达成的合规成就。该公司正在开发人工智能心电图解决方案，并努力获得其MyoVista® wavECG™设备的FDA批准。
Heart Test Laboratories, Inc.，也称HeartSciences，已成功恢复纳斯达克最低买入价格要求的合规性，这得到了纳斯达克证券市场有限责任公司于2024年6月3日收到的一封信的确认。该公司的普通股此前未能连续30个营业日满足每日最低收盘竞价为1.00美元的要求，导致在2023年8月2日，纳斯达克发出了不符合要求的通知。为了纠正这一状况，HeartSciences需要连续10个交易日保持收盘竞价至少为1.00美元，该条件已在2024年5月31日之前满足。因此，原定于2024年6月27日的上诉听证会已被取消，该公司的普通股和认股权证将继续在纳斯达克上市。利用人工智能改善心电图以早期检测心脏疾病的医疗技术公司HeartSciences于2024年6月4日发布新闻公告宣布了达成的合规成就。该公司正在开发人工智能心电图解决方案，并努力获得其MyoVista® wavECG™设备的FDA批准。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息